Page 55«..1020..54555657..60..»

You are currently browsing the Nano Medicine category

BENEO: Simply Healthier

§ May 8th, 2011 § Filed under Nano Medicine Comments Off on BENEO: Simply Healthier

BENEO, one of the leading manufacturers of functional ingredients, offers a range of solutions to enable sugar reduction in food products and prides itself on producing innovative ingredient solutions for food manufacturers. By concentrating on the taste, functionality and qualitative elements of a product, BENEO has developed its agglomerated sweeteners which are simple to integrate and provide a multitude of benefits. Here, Dr Thomas Walter, Head of Business Development at BENEO, provides insight into how its agglomerated sweeteners can be incorporated into products to provide sweetening solutions that are healthy and easy to use.

A review of the Mintel trend forecasts for 2011 shows that manufacturers are concentrating their efforts on product reformulations to ensure they meet the growing consumer demand for healthier nutrition. One of the major topics, sugar reduction, is still very high up on the food industry’s agenda. This issue is particularly pertinent as the entire sector prepares for the upcoming approval of Stevia, which claims to have mastered the delicate balancing act between calorie reduction and naturalness like no other intensive sweetener. The successful switch from saccharine, HFCS, fructose and glucose will allow food producers to make use of these ingredients in order to optimize their product offering with ease.

The use of agglomerated sweeteners is mainly for technological reasons. Agglomerates do not tend to dust or build up electrostatic energy and have a distinct flowability. This provides the producer with additional benefits, such as ease of transportation and use when measuring or filling. As they don’t absorb moisture, agglomerates can also be stored more easily. They dissolve quickly in fluids without forming lumps and, when consumed on their own, have a non-sandy texture in the mouth. The versatility of these agglomerates make them an excellent choice for use within ready-to-use instant drinks, compressed tablets, chewing gum and granulates, which are consumed with no water.

When several active and functional ingredients are used for the agglomeration, further advantages can be found. During the course of the agglomeration process, all of the elements are distributed evenly in the mixture, no matter how much or how little is used. An even distribution of the ingredient is therefore guaranteed, whether this is the sweet characteristic of an intensive sweetener such as Stevia, or the nutritionally enhanced profile of vitamins, or prebiotic fibres, such as inulin.

This article is available in full in the Spring 2011 issue of Nutraceuticals Now

Read the Rest...

Stevia rebaudiana: The Sweetener Power of Nature

§ May 8th, 2011 § Filed under Nano Medicine Comments Off on Stevia rebaudiana: The Sweetener Power of Nature

Reb A 97 GT the first class safe natural pure molecule of sweetness

The sweetness of Stevia’s leaves was well known for century and used by amerindians Guarinis which is called Kaâ-hè-é.

In 1899, the first detailled botanic ( and also sweetness) description was made by the swiss botanist Moisés Santiago Bertoni during his research in Eastern Paraguay.

The species Stevia rebaudiana, commonly known as sweetleaf, sweet leaf, sugarleaf, or simply stevia, is widely grown for its sweet leaves. As a sweetener and sugar substitute, stevia’s taste has a slower onset and longer duration than that of sugar, although some of its extracts may have a bitter or licorice-like aftertaste at high concentrations.

In 1931, the two french scientists Bridel and Lavielle have isolated and cristallised the compounds which were responsible of the sweet taste of Stevia rebaudiana, Bertoni. The exact chemical formula of steviolglycoside ( aglycone and glycoside) were publised in 1955. Now, more than 12 differents molecules, with the steviol aglycone, was isolated form differents variants of Stevia rebaudiana, B.

In 2008, the Coca-Cola Company with the giant agricultural processing Cargill have obtained the GRAS approval from the FDA for the Rebaudioside A with a purity > 97%.

In September 2009, the French government has followed the same way with a temporary autorisation as food additive for 2 years for the Rebaudioside A more than 97% of purity in order to wait the European Commission Directive.

In 2010, The NDA panel experts of .EFSA ( European Food Safety Agency) gave a positive opinion on the safety of Steviolglycosides ( a mixture of Rebaudioside A and Stevioside mainly) with a minimum purity of 95% expressed in dry basis.

This article is available in full in the Spring 2011 issue of Nutraceuticals Now

Read the Rest...

Forward to Spring 2011 Issue

§ May 8th, 2011 § Filed under Nano Medicine Comments Off on Forward to Spring 2011 Issue

A Sense of Proportion

The world is a challenging place at the moment. Although visitors to Vitafoods are rightly focused on the product, pricing, regulatory and marketing problems and opportunities of their industries, the bigger picture matters to us too.

The widespread unrest in the Middle East with ‘people- power’ is changing long-standing political and strategic landscapes. Unrest in Tunisia and Egypt has led to changes of government and a coalition of nations has launched air attacks on military targets in Libya. Japan is still reeling from the tragedy of the recent earthquake, the resulting tsunami and desperate attempts to control damaged nuclear facilities at Fukishima. All this, while the global economy remains fragile (if not downright depressed) following the banking and financial crises of 2008/2009. Global markets, equities and currencies are volatile as traders and governments try to map a way forward out of the confusion.

In its own small way, the food industry reflects this crux. The rapidly rising price of staple food has been blamed for triggering much of the unrest in the Middle East and raising tensions elsewhere. Increased commodity, processing and packaging costs (due to rising oil prices) are impacting prices globally with the World Bank quoting a 15% increase in food prices in the four months between October 2010 and January 2011. In the UK, food price inflation is running at a reported 6.3% and in the USA, Feeding America reported a 46% increase in the number of people in the USA needing their assistance. Record numbers of floods, typhoons and unseasonal heat-waves, whether the result of global warming or some other factor, are impacting on the size and quality of agricultural crops and reducing the availability of good farmland. And all this at a time when scientists and agronomists are trying to find ways of meeting the challenge of feeding a rising world population which will reach 7 billion this year, up from 5 billion 20 years ago.

With disposable income likely to fall over the next 2 or 3 years, consumers will question every expenditure. Can the cost of dietary supplements and/or the additional premium of dietary supplements or functional foods be justified when staple ingredients need to be bought and the family needs to be fed?

Industry growth plans will have to address this fundamental question by investing in good marketing. Marketing that keeps the consumer interested, informed and persuaded of the benefits and value of its products, even when budgets are tight. But here’s another problem: just as consumer budgets are likely to be at their tightest, the strictures and limitations of EFSA’s rulings will begin to apply.

Our industry’s problems are trivial in comparison to much of what is happening in the world today. But for dietary supplement and functional foods manufacturers, and their customers, the storm clouds developing over Palma (where EFSA is based) still threaten to do serious damage. Only
by working constructively and creatively will we be able to navigate our way to a healthy and profitable future.

Henry Dixon
Commercial Director, Barrett Dixon Bell

Read the Rest...

Aenova Group: New Effervescent Product

§ May 8th, 2011 § Filed under Nano Medicine Comments Off on Aenova Group: New Effervescent Product

The new product range from the Aenova Group offers a selection of high-quality and exclusive effervescent products, thus extending the company’s range and offering its customers the opportunity to stand out from the established mass market.

The new high-quality effervescent product range from the Aenova Group expands its portfolio and emphasises its position as one of the world’s largest suppliers of solid oral administration forms for the pharmaceutical and healthcare industry. The Aenova Group is one of the few companies in the branch to offer a full-service portfolio encompassing the purchasing of raw materials, analytics, packaging and logistics, alongside manufacturing and production. The ongoing objective of the company is the continual development of new product concepts and products which are tailored to the needs of customers and markets. Thus, since May 2010, Aenova has been offering a standard range of a variety of dietary supplements which cover different indication ranges. This standard product range has enabled the company to expand its customer services and create time-saving and cost-effective solutions for the international dietary supplements market.

With the new effervescent product range, Aenova has provided a diverse selection of high-quality and unique effervescent products. High-quality products which demonstrate particularly good market potential and correspond to current trends are developed on the basis of detailed market analyses, coupled with longstanding know-how and in-depth market knowledge.

This article is available in full in the Spring 2011 issue of Nutraceuticals Now

Read the Rest...

International Stem Cell Corporation Chairman Presents Summary of Achievements at Annual Shareholders’ Meeting

§ May 8th, 2011 § Filed under Nano Medicine Comments Off on International Stem Cell Corporation Chairman Presents Summary of Achievements at Annual Shareholders’ Meeting

CARLSBAD, Calif. (May 05, 2011) - At the annual shareholders meeting of International Stem Cell Corporation (OTCBB:ISCO) on May 3, 2011, Kenneth Aldrich, Chairman and co-founder of ISCO conducted a presentation to shareholders that included the following remarks:

Good morning to all our shareholders and friends of ISCO. Let me make just a few comments about where we are and the progress we have made over the last year. All of the developments and news I will discuss were announced in the past 12 months, but with the passage of time it is easy to lose track of how much progress ISCO has actually made. I won’t mention everything—we don’t have that much time, but some highlights will, I hope, help put these recent achievements into perspective.

A little less than a year ago, in June 2010, our first parthenogenetic patent application was formally approved by the US Patent Office. More applications are pending, but this approval established ISCO as the lawful owner of the rights to produce human stem cell lines through parthenogenesis. That is a platform on which we expect to build for a long time.

Also in June we eliminated all of our outstanding corporate debt and we remain debt free.

In July we announced the signing of a distribution contract with Sristi Biosciences, a major seller of research products in India, which continues the international commercial expansion of our Lifeline Cell Technology® brand.

In October we announced the first steps toward the formation of a major funded collaboration in India with Insight Bioventures India Private Limited (IBVI) to develop treatments for corneal damage and retinal disease. Planning for that work is ongoing and the Executive Director of Insight Bioventures has flown in from India to meet with us today, so we remain very optimistic about this project.

In November, we presented the results of scientific studies demonstrating a new and better method for differentiating our parthenogenetic cells into liver cells, a critical step toward using them to treat liver disease.

In November and December we launched the first test marketing runs of our new skin crème products, first to our own shareholders and friends, then to a select mailing list developed by our marketing partner, John Mauldin. Those resulted in sales of over 7,000 bottles of our new products.

In December we established $25 million financing commitment that provides access to capital on an as-needed basis over a three year period, but never requires the sale of stock unless we think it will benefit the company and its shareholders. This agreement provides us a high degree of flexibility in meeting our financial needs.

In January 2011 we announced publication of peer-reviewed studies further validating the functional equivalency of our parthenogenetic stem cells with embryonic stem cells. These studies confirm our ability to benefit from much of the millions of dollars of research on embryonic stem cells over the last decade. In short, we have a running start in the search for cures.

Throughout the year we have made steady progress in development of liver cells and liver precursor cells, culminating in an announcement in April of this year that we had successfully completed the first in a series of pre-clinical tests of parthenogenetically derived liver cells.

Last, but by no means least, we have received the necessary approvals for creating new Parthenogenetic Stem Cell Lines in the United States. These will be clinical grade lines suitable for human trials, and are the first major step in this country to begin building a “Bank” of stem cells enabling the matching of immune systems of millions of people worldwide, with the potential to eliminate or reduce the harmful effects of immune suppressing drugs that would normally have to be used with stem cell transplant procedures.

All of these news stories and more are available on our website along with presentations we have made recently to investors in the US and Europe. On behalf of the Board of Directors and everyone at ISCO, I thank you for your support.

About International Stem Cell Corporation

International Stem Cell Corporation is focused on the therapeutic applications of human parthenogenetic stem cells and the development and commercialization of cell-based research and cosmetic products. ISCO's core technology, parthenogenesis, results in the creation of pluripotent human stem cells from unfertilized oocytes (eggs). hpSCs avoid ethical issues associated with the use or destruction of viable human embryos. ISCO scientists have created the first parthenogenic, homozygous stem cell line that can be a source of therapeutic cells with minimal immune rejection after transplantation into hundreds of millions of individuals of differing genders, ages and racial background. This offers the potential to create the first true stem cell bank, UniStemCell™. ISCO also produces and markets specialized cells and growth media for therapeutic research worldwide through its subsidiary Lifeline Cell Technology, and cell-based skin care products through its subsidiary Lifeline Skin Care. More information is available at http://www.internationalstemcell.com.

To subscribe to receive ongoing corporate communications, please click on the following link: http://www.b2i.us/irpass.asp?BzID=1468&to=ea&s=0.

Forward-looking Statements

Statements pertaining to anticipated developments, product introduction plans and related support, the potential benefits of products, and other opportunities for the company and its subsidiaries, along with other statements about the future expectations, beliefs, goals, plans, or prospects expressed by management constitute forward-looking statements. Any statements that are not historical fact (including, but not limited to statements that contain words such as "will," "believes," "plans," "anticipates," "expects," "estimates,") should also be considered to be forward-looking statements. Forward-looking statements involve risks and uncertainties, including, without limitation, risks inherent in the development and/or commercialization of potential products and the management of collaborations, regulatory approvals, need and ability to obtain future capital, application of capital resources among competing uses, and maintenance of intellectual property rights. Actual results may differ materially from the results anticipated in these forward-looking statements and as such should be evaluated together with the many uncertainties that affect the company's business, particularly those mentioned in the cautionary statements found in the company's Securities and Exchange Commission filings. The company disclaims any intent or obligation to update forward-looking statements.

Contact:

International Stem Cell Corporation

Kenneth C Aldrich, Chairman

760-940-6383

kaldrich@intlstemcell.com

# # #

Read the Rest...

Nanomedicine: Release of neurological drugs

§ May 5th, 2011 § Filed under Nano Medicine Comments Off on Nanomedicine: Release of neurological drugs

Nanomedicine Catalytic: Release of Neurological drugs

Read this article:

Nanomedicine: Release of neurological drugs

Read the Rest...

International Stem Cell Corporation Completes First Series of Pre-Clinical Testing of Hepatocytes Derived from Human Parthenogenetic Stem Cells

§ May 1st, 2011 § Filed under Nano Medicine Comments Off on International Stem Cell Corporation Completes First Series of Pre-Clinical Testing of Hepatocytes Derived from Human Parthenogenetic Stem Cells

Data from successful animal study using liver cells derived from human parthenogenetic stem cells to be presented at two upcoming scientific conferences

Company also announces collaboration with Cedars-Sinai Medical Center for liver disease research, and completion of research on cytochrome P450 activity

International Stem Cell Corporation (OTCBB:ISCO) (ISCO) announces successful completion of the first series of preclinical testing of hepatocytes derived in the lab from human parthenogenetic stem cells (hpSC). In the transplantation mouse model, inoculated cells were capable of engrafting and surviving in specific niches within the liver, and were further developing into cells with essential hepatocyte-like features. Moreover, the transplanted cells could be identified in recipient tissue for a prolonged period of time.

The findings of these studies will be presented at the annual meeting of American Society of Gene & Cell Therapy, May 18-21 in Seattle, and at the International Society for Stem Cell Research annual conference, June 15-18 in Toronto.

"These results mark the achievement of a key milestone in our preclinical research," said Andrey Semechkin, Ph.D., ISCO's Chief Executive Officer. "Specifically, we have perfected the technique to transplant hepatocytes, an extremely fragile cell type, into the liver of animals, which is an easily injured organ. This preclinical research helps us develop our collaborations with clinics."

Nikolay Turovets, Ph.D., ISCO's Director of Research and Therapeutic Development commented "The next phase of research is to conduct experiments to demonstrate the ability of the transplanted cells to perform the vital functions of normal hepatocytes and, accordingly, their ability to modify disease by restoring the missing function of a patient's diseased liver."

The Company also announces the signing of a joint collaboration agreement with Cedars-Sinai Medical Center in Los Angeles to conduct research to develop therapies for liver diseases, in particular urea cycle disorders. Jeffrey Fair, MD., a liver transplant surgeon and Director of Translational Research for the Cedars-Sinai Comprehensive Transplant Center and Department of Surgery, will lead the Cedars-Sinai research team.

Dr. Fair said, "Urea cycle disorders are genetic deficiencies of liver function, which mostly affect newborns and oftentimes cause catastrophic neurological injury. It has been shown that transplantation of donor hepatocytes can save patient lives. Therefore, derivation of hepatocytes from hpSCs that can be immune-matched to the patient is a very pressing goal."

The Company also announces the completion of research focused on the investigation of cytochrome P450 activity and corresponding genes in hepatocytes derived from hpSC. According to the results, the differentiation technology developed by ISCO allows the creation of hepatocytes in the fetal stage of development. This research may contribute to the design of a product for future drug testing and discovery.

About International Stem Cell Corporation

International Stem Cell Corporation is focused on the therapeutic applications of human parthenogenetic stem cells and the development and commercialization of cell-based research and cosmetic products. ISCO's core technology, parthenogenesis, results in the creation of pluripotent human stem cells from unfertilized oocytes (eggs). hpSCs avoid ethical issues associated with the use or destruction of viable human embryos. ISCO scientists have created the first parthenogenic, homozygous stem cell line that can be a source of therapeutic cells with minimal immune rejection after transplantation into hundreds of millions of individuals of differing genders, ages and racial background. This offers the potential to create the first true stem cell bank, UniStemCell™. ISCO also produces and markets specialized cells and growth media for therapeutic research worldwide through its subsidiary Lifeline Cell Technology, and cell-based skin care products through its subsidiary Lifeline Skin Care. More information is available at http://www.internationalstemcell.com.

To subscribe to receive ongoing corporate communications, please click on the following link:http://www.b2i.us/irpass.asp?BzID=1468&to=ea&s=0.

Forward-looking Statements

Statements pertaining to anticipated developments, research and development goals and related potential therapeutic treatments, the potential benefits of products, and other opportunities for the company and its subsidiaries, along with other statements about the future expectations, beliefs, goals, plans, or prospects expressed by management constitute forward-looking statements. Any statements that are not historical fact (including, but not limited to statements that contain words such as "will," "believes," "plans," "anticipates," "expects," "estimates,") should also be considered to be forward-looking statements. Forward-looking statements involve risks and uncertainties, including, without limitation, risks inherent in the development and/or commercialization of potential products and the management of collaborations, regulatory approvals, need and ability to obtain future capital, application of capital resources among competing uses, and maintenance of intellectual property rights. Actual results may differ materially from the results anticipated in these forward-looking statements and as such should be evaluated together with the many uncertainties that affect the company's business, particularly those mentioned in the cautionary statements found in the company's Securities and Exchange Commission filings. The company disclaims any intent or obligation to update forward-looking statements.

http://cts.businesswire.com/ct/CT?id=bwnews&sty=20110426005697r1&sid=14230&distro=ftp

International Stem Cell Corporation
Kenneth C Aldrich, Chairman
760-940-6383
kaldrich@intlstemcell.com

or
Nikolay Turovets, Ph.D.
Director, Research and Therapeutic Development
nturovets@intlstemcell.com

Read the Rest...

International Stem Cell Corporation Updates on Marketing Strategy of Its Subsidiary Lifeline Skin Care

§ April 24th, 2011 § Filed under Nano Medicine Comments Off on International Stem Cell Corporation Updates on Marketing Strategy of Its Subsidiary Lifeline Skin Care

International Stem Cell Corporation (OTCBB:ISCO) http://www.internationalstemcell.com, a California-based biotechnology company focused on therapeutic and research products, announced today the selection of the Richards Partners as agency of record for its wholly owned subsidiary Lifeline Skin Care, Inc. ("Lifeline"). Lifeline offers luxury anti-aging skin care products based on its proprietary stem cell technology. Based in Dallas, the Richards Partners is the nation's largest independent branding agency.

Lifeline's skin care products were developed by a team of ISCO research scientists in collaboration with world-renowned cosmetic experts, and offer a comprehensive approach to skin care using patent pending moisture serums for day and night use. Made with human parthenogenetic stem cell extracts, the serums deliver anti-aging benefits, resulting in healthier and younger-looking skin. These products were launched in November 2010 and are available for purchase through the http://www.lifelineskincare.com website and selected luxury spas across the United States.

Adding Richards Partners to the Lifeline Skin CareTM team is part of Lifeline's plan to build on its initial successful product launch last year, and the Web based sales that have followed, by initiating a series of new marketing campaigns to further develop the Lifeline Skin CareTMbrand identity. These new marketing initiatives include traditional print and news media campaigns, as well as a new digital strategy focused on Internet and social media. "We are looking forward to working closely with the Richards Partners and leveraging their expertise in these areas to enhance the profile of Lifeline Skin CareTM and its revolutionary new skin care products," says Lifeline CEO Ruslan Semechkin, PhD. "Building a globally recognizable brand is a long-term process and this is an important step towards creating Lifeline's name. We believe this is a good time to begin these campaigns and continue our sales momentum resulting from our successful initial launch," Dr. Semechkin continued.

As previously announced the Mauldin Group, Lifeline's marketing partner, will be managing the day to day relationship with the Richards Partners and planning additional direct marketing initiatives similar to the successful initial launch in 2010. Tiffani Mauldin-Frederick, marketing partner of Lifeline Skin CareTM, says, "We're excited about working together with Richards Partners. We believe the collaboration will provide additional momentum and increase brand recognition for Lifeline Skin CareTM and help educate the public about the revolutionary science behind these products."

ABOUT INTERNATIONAL STEM CELL CORPORATION (ISCO.OB)

International Stem Cell Corporation is a California-based biotechnology company focused on the therapeutic applications of human parthenogenetic stem cells and the development and commercialization of cell-based research and cosmetic products. ISCO's core technology, parthenogenesis, results in creation of pluripotent human stem cells from unfertilized oocytes (eggs). hpSCs avoid ethical issues associated with the use or destruction of viable human embryos. ISCO scientists have created the first parthenogenic, homozygous stem cell line that can be a source of therapeutic cells with minimal immune rejection after transplantation into hundreds of millions of individuals of differing sexes, ages and racial groups. This offers the potential to create the first true stem cell bank, UniStemCell™, while avoiding the ethical issue of using fertilized eggs. ISCO also produces and markets specialized cells and growth media for therapeutic research worldwide through its subsidiary Lifeline Cell Technology and cell-based skin care products through its subsidiary Lifeline Skin Care. More information is available at ISCO's website, http://www.internationalstemcell.com.

To subscribe to receive ongoing corporate communications please click on the following link:http://www.b2i.us/irpass.asp?BzID=1468&to=ea&s=0.

FORWARD-LOOKING STATEMENTS

Statements pertaining to anticipated developments, product introduction plans and related support, the potential benefits of products, and other opportunities for the company and its subsidiaries, along with other statements about the future expectations, beliefs, goals, plans, or prospects expressed by management constitute forward-looking statements. Any statements that are not historical fact (including, but not limited to statements that contain words such as "will," "believes," "plans," "anticipates," "expects," "estimates,") should also be considered to be forward-looking statements. Forward-looking statements involve risks and uncertainties, including, without limitation, risks inherent in the development and/or commercialization of potential products and the management of collaborations, regulatory approvals, need and ability to obtain future capital, application of capital resources among competing uses, and maintenance of intellectual property rights. Actual results may differ materially from the results anticipated in these forward-looking statements and as such should be evaluated together with the many uncertainties that affect the company's business, particularly those mentioned in the cautionary statements found in the company's Securities and Exchange Commission filings. The company disclaims any intent or obligation to update forward-looking statements.

Key Words: Stem cells, parthenogenesis, biotechnology, skin care, anti-aging

http://cts.businesswire.com/ct/CT?id=bwnews&sty=20110419005649r1&sid=14230&distro=ftp

International Stem Cell Corporation
Kenneth C. Aldrich, Chairman
1-760-940-6383
kaldrich@intlstemcell.com

or
Lifeline Skin Care, Inc.
Ruslan Semechkin, PhD, President & CEO
Vice President, ISCO
ras@intlstemcell.com

Read the Rest...

Part 1: Nanomedicine Expert Ralph Merkle, PhD

§ April 18th, 2011 § Filed under Nano Medicine Comments Off on Part 1: Nanomedicine Expert Ralph Merkle, PhD

Institute for Molecular Manufacture Senior Fellow on the development of nanofactories and the implications of building "medical nanorobots" that can keep people alive and healthy, thereby radically extending lifespans. More information at manhattanbeachproject.com Updates at http

Go here to read the rest:

Part 1: Nanomedicine Expert Ralph Merkle, PhD

Read the Rest...

Proactiveinvestors Completes First European Presentations with NeoStem and International Stem Cell Corp

§ April 3rd, 2011 § Filed under Nano Medicine Comments Off on Proactiveinvestors Completes First European Presentations with NeoStem and International Stem Cell Corp

Proactiveinvestors completed its first investor forums in mainland Europe, in partnership with Milestone Media, last week, hosting presentations in Zurich and Munich with US listed companies NeoStem (AMEX:NBS) and International Stem Cell Corporation (OTC:ISCO).

Both investor forums were a great success, with notable attendees including Infidar Investment Advisory, BB Bellevue Asset Management, Centrum Bank, Taylor Wessing, BVMW and UBS Global Asset Management.

NeoStem’s CEO and Chairman Robin Smith updated investors on the company’s adult stem cell operations in the U.S., network of adult stem cell therapeutic providers in China, and recent acquisition of a 51% interest in a profitable Chinese generic pharmaceutical manufacturing company.

The company is focused on accelerating the development of proprietary cellular therapies and becoming a single source for collection, storage, manufacturing, therapeutic development and transportation of cells for cell based medicine and regenerative science globally.

NeoStem was recently given an initial "outperform" rating from US equity research firm Cowen, based on recent acquisitions and tie ups strengthening the company's adult stem cell banking capabilities.

Ken Aldrich, Chairman and Co-Founder of International Stem Cell Corporation also had plenty to introduce to European audiences. The California-based biotechnology company is focused on the therapeutic applications of human stem cells and the development and commercialization of cell-based research and cosmetic products.

The company’s core technology, Parthenogenesis, results in creation of pluripotent human stem cells from unfertilized oocytes. This technique avoids ethical issues associated with the use or destruction of viable human embryos and can be a source of therapeutic cells that minimize or eliminate immune rejection after transplantation into the patient.

Read the Rest...

nanomedicine: nanotechnology for cancer treatment

§ April 2nd, 2011 § Filed under Nano Medicine Comments Off on nanomedicine: nanotechnology for cancer treatment

Solving radiotherapy s biggest limitation. Medicine is now using physics every day to treat cancer patients. Nanotechnologies can help clinicians deliver safer and more efficient treatments by shifting the intended effect from the macroscopic to the subcellular level

Read more:

nanomedicine: nanotechnology for cancer treatment

Read the Rest...

Nano 3 @ Calit2 – Nanoscience, Nanoengineering, Nanomedicine

§ April 1st, 2011 § Filed under Nano Medicine Comments Off on Nano 3 @ Calit2 – Nanoscience, Nanoengineering, Nanomedicine

nano3.calit2.net Nano3 provides advanced capabilities for fabrication and characterization in a state-of-the-art cleanroom opened in May 2006. The name Nano3 reflects the synergetic nature of the facility, focusing on three fields of nanoscale research and development within the space - Nanoscience, Nanoengineering and Nanomedicine. In addition to providing essential nanofabrication capabilities for research on electronic and optoelectronic materials and devices, the facility is intended to facilitate the pursuit of research in emerging, interdisciplinary, and rapidly growing fields such as biomedical and biochemical devices, heterogeneous integrated devices and circuits, and sensor technology.

Originally posted here:

Nano 3 @ Calit2 - Nanoscience, Nanoengineering, Nanomedicine

Read the Rest...

NanoMedicine Cancer Drug Delivery

§ March 31st, 2011 § Filed under Nano Medicine Comments Off on NanoMedicine Cancer Drug Delivery

NanoMission - NanoMedicine Module : Take control as a biomedical scientist! Help to cure cancer through observation and experimentation by building nanoscopic particles and measuring their effects on the patient at the cellular level. Visit http://www.nanomission.org to Download the game!

Link:

NanoMedicine Cancer Drug Delivery

Read the Rest...

What is Nanomedicine?

§ March 23rd, 2011 § Filed under Nano Medicine Comments Off on What is Nanomedicine?

A brief intro to the NISE Network's Nanomedicine Exhibit. To learn more about the exhibit, check out nisenet.org/catalog.

Read more:

What is Nanomedicine?

Read the Rest...

Kenneth Aldrich, Executive Chairman of International Stem Cell Corporation, will make a public appearance on March 16th, 2011 on behalf of ISCO

§ March 13th, 2011 § Filed under Nano Medicine Comments Off on Kenneth Aldrich, Executive Chairman of International Stem Cell Corporation, will make a public appearance on March 16th, 2011 on behalf of ISCO

OCEANSIDE, Calif. -- (March 10, 2011) -- International Stem Cell Corporation (OTCBB:ISCO), http://www.internationalstemcell.com, announced today that its Executive Chairman, Kenneth C. Aldrich, will present at the ROTH 23rd Annual Orange County Growth Stock Conference at the Ritz Carlton Laguna Niguel in Dana Point, CA. on Wednesday, March 16, 2011 at 10:30 AM PDT (1:30PM EDT). The webcast can be viewed live at: http://www.wsw.com/webcast/roth24/isco/. The presentation will be archived and viewable at the same link for 90 days. After the Roth Conference, a link to the presentation will also be posted to the ISCO website, http://www.internationalstemcell.com.

ABOUT INTERNATIONAL STEM CELL CORPORATION (ISCO.OB)

International Stem Cell Corporation is a California-based biotechnology company focused on therapeutic and research products. ISCO's core technology, parthenogenesis, results in creation of pluripotent human stem cells from unfertilized oocytes (eggs). These proprietary cells avoid ethical issues associated with use or destruction of viable human embryos and, unlike most other major stem cell types, can be immune matched and be a source of therapeutic cells with minimal rejection after transplantation into hundreds of millions of individuals of differing racial groups. ISCO also produces and markets specialized cells and growth media for therapeutic research worldwide through its subsidiary, Lifeline Cell Technology, and has developed cell based skin care products through its subsidiary, Lifeline Skin Care. ISCO is advancing novel human stem cell-based therapies where cells have been proven to be efficacious but traditional small molecule and protein therapeutics have not. More information is available on ISCO's website, http://www.internationalstemcell.com.

To subscribe to receive ongoing corporate communications please click on the following link: http://www.b2i.us/irpass.asp?BzID=1468&to=ea&s=0 .

Key Words: Stem cells, parthenogenesis, biotechnology, skin care

CONTACTS

International Stem Cell Corporation

Kenneth C. Aldrich, Executive Chairman

1-760-940-6383

kaldrich@intlstemcell.com

Read the Rest...

International Stem Cell Corporation Receives Important Approvals Towards Creating New Parthenogenetic Stem Cell Lines in the United States

§ March 9th, 2011 § Filed under Nano Medicine Comments Off on International Stem Cell Corporation Receives Important Approvals Towards Creating New Parthenogenetic Stem Cell Lines in the United States

International Stem Cell Corporation (OTCBB:ISCO), http://www.internationalstemcell.com, announced today the achievement of a major milestone in its efforts to establish a bank of immune-matched parthenogenetic stem cells in the United States by receiving the statutory approvals required to move forward with the next phase of its stem cell banking program.


An independent Stem Cell Research Oversight (SCRO) committee approved ISCO's program to obtain human oocytes (eggs) in California. The independent SCRO committee is responsible for reviewing the scientific rationale, ethics and compliance with State and Federal regulations and guidelines for studies involving human stem cells. This approval in combination with the earlier reported Institutional Review Board (IRB) clearance with regard to medical safety opens the way for ISCO's stem cell banking program to begin registering clinical investigators. ISCO's study is designed to produce new clinical-grade human parthenogenetic stem cell lines that can be immune matched to millions of individuals for use in the emerging field of regenerative medicine.


ISCO's breakthrough discoveries have resulted in unique stem cells carrying distinct advantages over other human pluripotent stem cells. ISCO uses unfertilized oocytes to create human "parthenogenetic" stem cells (hpSCs). Like human embryonic stem cells (hESCs), hpSCs are pluripotent, i.e. they have the capacity to become almost any cell type in the body, yet avoid ethical issues associated with use or destruction of viable human embryos. Unlike hESCs, hpSCs can be created in a form such that they can be immunologically matched to millions of individuals.


Currently ISCO has a collection of ten hpSC lines that are shared with collaborators and used for research purposes. Although these ten stem cell lines conform to all relevant US standards, they were derived outside the United States. New cell lines created under this study will be ISCO's first hpSC to be produced in the United States. ISCO's scientists, leaders the field of creating therapeutic cells from hpSC, will work with these lines targeting new treatments for human diseases. The company will also share these cells with other scientists to further clinical research. ISCO intends to derive and store these cells at its Oceanside facilities, which are designed to create cells suitable for clinical use.


Simon Craw, PhD, says, "These approvals, combined with our technology, make the establishment of a bank of immune matched stem cells practical and allow for the possibility of cell-based therapy to be economic for millions of people. We believe we are one of the first commercial entities in the United States to have progressed to this point."


ABOUT INTERNATIONAL STEM CELL CORPORATION (ISCO.OB):

International Stem Cell Corporation is a California-based biotechnology company focused on the therapeutic applications of human parthenogenetic stem cells and the development and commercialization of cell-based research and cosmetic products. ISCO's core technology, parthenogenesis, results in creation of pluripotent human stem cells from unfertilized oocytes (eggs). hpSCs avoid ethical issues associated with the use or destruction of viable human embryos. ISCO scientists have created the first parthenogenic, homozygous stem cell line that can be a source of therapeutic cells with minimal immune rejection after transplantation into hundreds of millions of individuals of differing sexes, ages and racial groups. This offers the potential to create the first true stem cell bank, UniStemCell™, while avoiding the ethical issue of using fertilized eggs. ISCO also produces and markets specialized cells and growth media for therapeutic research worldwide through its subsidiary Lifeline Cell Technology and cell-based skin care products through its subsidiary Lifeline Skin Care. More information is available at ISCO's website, http://www.internationalstemcell.com


To subscribe to receive ongoing corporate communications please click on the following link: http://www.b2i.us/irpass.asp?BzID=1468&to=ea&s=0.


FORWARD-LOOKING STATEMENTS

Statements pertaining to anticipated technological developments and therapeutic applications, the potential benefits of collaborations, and other opportunities for the company and its subsidiaries, along with other statements about the future expectations, beliefs, goals, plans, or prospects expressed by management constitute forward-looking statements. Any statements that are not historical fact (including, but not limited to statements that contain words such as "will," "should," "believes," "plans," "anticipates," "expects," "estimates,") should also be considered to be forward-looking statements. Forward-looking statements involve risks and uncertainties, including, without limitation, risks inherent in the development and/or commercialization of potential products and therapies, uncertainty in the results of clinical trials or regulatory approvals, need and ability to obtain future capital, application of capital resources among competing uses, and maintenance of intellectual property rights. Actual results may differ materially from the results anticipated in these forward-looking statements and as such should be evaluated together with the many uncertainties that affect the company's business, particularly those mentioned in the cautionary statements found in the company's Securities and Exchange Commission filings. The company disclaims any intent or obligation to update these forward-looking statements.


Key Words: Stem Cells, Biotechnology, Parthenogenesis


http://cts.businesswire.com/ct/CT?id=bwnews&sty=20110309005570r1&sid=14230&distro=ftp

International Stem Cell Corporation
Kenneth C. Aldrich, Chairman
760-940-6383
kaldrich@intlstemcell.com

Or
Simon Craw, PhD, Vice President
760-940-6383
sc@intlstemcell.com

Read the Rest...

Obesity in the Workplace Costs Employers Billions

§ March 6th, 2011 § Filed under Nano Medicine Comments Off on Obesity in the Workplace Costs Employers Billions

A recent study published in the Journal of Occupational and Environmental Medicine revealed that work-related factors may impact the total cost of obesity among U.S. full-time employees even more than direct medical costs. The Duke University research team reported the total per capita cost to employers of obesity among U.S. full-time employees to be a staggering $73.1 billion. The researchers reportedly factored in for the first time the total value of lost job productivity as a result of obesity-related health problems (presenteeism) and absence from work (absenteeism). The study included data from the 2006 Medical Expenditure Panel Survey and the 2008 U.S. National Health and Wellness Survey in the evaluation of individuals who were normal weight, overweight and obese, using body mass index calculations (BMI). While presenteeism was determined to represent the largest cost among employees at a healthy weight, researchers found that obese workers accounted for a disproportionately larger share of overall presenteeism, absenteeism and medical expenses. Further, obese individuals with a BMI greater than 35 represented 61 percent of all obese employee costs, though they represent only 37 percent of the overall obese population.

 
The study is available here.
Obesity in the Workplace Costs Employers Billions

Read the Rest...

"A Little Egg On the Face" – LifeLine Skin Care Stem Cell Cream Article

§ March 6th, 2011 § Filed under Nano Medicine Comments Off on "A Little Egg On the Face" – LifeLine Skin Care Stem Cell Cream Article

"A Little Egg On the Face" by Rebecca Tolin (read San Diego Magazine article here )

Women have been known to slather their faces with fruit, fish oil, foreskin (uh huh, the target of circumcision) and even the neurotoxin that causes botulism?—?all in the name of looking pretty. Now an Oceanside biotech has another novel ingredient for the aging-averse: stem cells from unfertilized human eggs.

“It’s not like a woman donated eggs in Encinitas and three months later it’s in someone’s skin in L.A.,” explains Brian Lundstrom, president of International Stem Cell Corporation (ISSC) in Oceanside, parent company of Lifeline Skin Care. It’s more like this: Women go to in-vitro fertilization clinics to get pregnant. There are often leftover eggs from that process. Researchers select stem cells, grow billions of them, and extract the bits that skin loves, such as growth factors?—?with permission from the donors, of course. Scientists then whip ’em up with antioxidants and sell the stuff in a slick plastic tube for about the cost of a month’s supply of Frappuccinos.

Is this a noncaffeinated fountain of youth? Ruslan Semechkin, the CEO of Lifeline and a biologist by training, says an eight-week study showed the day-and-night serum combo reduced the number and depth of wrinkles and made skin brighter, tighter and moister?—?though he wouldn’t say by how much. (Semechkin is 25, has the olive-tinged skin of a baby and admits a complexion of his variety doesn’t need this heavy hitter.)
Even in the stem cell world, youth is coveted. Lundstrom says stem cells taken from unfertilized eggs?—?the very seeds of life?—?are the youngest around and can become any cell in the human body. This is the first time such stem cell fragments have found their way into beauty cream, he explains. And because the eggs aren’t fertilized, they bypass the embryo controversy.

Someday, movement in the paralyzed and memory in the aged could be restored by using such cells; ISSC has already grown a human cornea that could cure blindness in people with eye damage. These breakthroughs may be dec­ades away, but ISSC’s “cosmeceuticals” are just the beginning. Profits from pocketbooks of the age-obsessed will fund the biotech’s research for other therapeutic drugs. So if you’re considering spending a small fortune to plump things up, you could call it a contribution to science.

Lifeline Defensive Day Moisture Serum sells for $155 and Lifeline Recovery Night Moisture Serum costs $185. It’s available at lifelineskincare.com.

Read the Rest...

International Stem Cell Corporation Updates on 2010 Initial Product Launch of its Lifeline Skin Care Products

§ March 6th, 2011 § Filed under Nano Medicine Comments Off on International Stem Cell Corporation Updates on 2010 Initial Product Launch of its Lifeline Skin Care Products

International Stem Cell Corporation (OTCBB:ISCO), http://www.internationalstemcell.com, announced today that its wholly owned subsidiary Lifeline Skin Care, Inc. ("LSC"), has now completed its evaluation of the highly successful trial launch of its new stem cell skin care product line in November and December 2010, and will move forward with its general marketing program.


Lifeline Skin Care products contain parthenogenetic stem cell extract and were developed by the ISCO research team in collaboration with world recognized cosmetic chemists. The breakthrough products deliver leading advances in skin rejuvenation technology that help to prevent and repair damaged skin. The products are available through our online store at http://www.lifelineskincare.com.


"Sales to date have greatly exceeded our expectations for the trial launch. These initial sales resulted from a very limited product offering made to subscribers of only one of the several newsletters of our marketing partner, John Mauldin, plus a small direct mailing to interested parties and ISCO's shareholders who had signed up for general corporate information through the ISCO website," said Dr. Ruslan Semechkin, CEO of Lifeline Skin Care.


Lifeline Skin Care is now ready to move forward to the next phase of distribution, which will commence near the end of March. That phase will consist initially of a customer solicitation conducted by John Mauldin's specialty Internet and direct response marketing organization. "We almost never endorse or sell a retail product," said Mr. Mauldin, "but the results of both our informal testing and the company's formal studies have convinced us that the Lifeline Skin Care products really are a game-changing advance in skin care. I have not seen such a strong response in online marketing in the last ten years. We are all very excited and proud to be involved."


Kenneth Aldrich, Chairman of ISCO, issued a cautionary comment to its investors. "We are incredibly excited by the prospects of this new product from our Lifeline Skin Care subsidiary. Selling over 7,000 bottles through a very limited trial launch, as we have done, represents a significant first step, but it would be imprudent for us to base projections of future sales or profits on a sample base of this size."


ISCO investors should note that under ISCO's current revenue recognition policy, a large portion of the Q-4 2010 sales will not be included as revenue in the financial statements for the year ended December 31, 2010. Sales of these products meet our revenue recognition criteria after our 30 day product guarantee period has been completed.


ABOUT INTERNATIONAL STEM CELL CORPORATION (ISCO.OB)

International Stem Cell Corporation is a California-based biotechnology company focused on therapeutic and research products. ISCO's core technology, parthenogenesis, results in creation of pluripotent human stem cells from unfertilized oocytes (eggs). These proprietary cells avoid ethical issues associated with use or destruction of viable human embryos and, unlike most other major stem cell types, can be immune matched and be a source of therapeutic cells with minimal rejection after transplantation into hundreds of millions of individuals of differing racial groups. ISCO also produces and markets specialized cells and growth media for therapeutic research worldwide through its subsidiary, Lifeline Cell Technology, and has developed cell based skin care products through its subsidiary, Lifeline Skin Care. ISCO is advancing novel human stem cell-based therapies where cells have been proven to be efficacious but traditional small molecule and protein therapeutics have not. More information is available on ISCO's website, http://www.internationalstemcell.com.


To subscribe to receive ongoing corporate communications please click on the following link: http://www.b2i.us/irpass.asp?BzID=1468&to=ea&s=0.


FORWARD-LOOKING STATEMENTS

Statements pertaining to anticipated developments, product marketing plans, the potential benefits of collaborations, affiliations, and other opportunities for the company and its subsidiaries, along with other statements about the future expectations, beliefs, goals, plans, or prospects expressed by management constitute forward-looking statements. Any statements that are not historical fact (including, but not limited to statements that contain words such as "will," "believes," "plans," "anticipates," "expects," "estimates,") should also be considered to be forward-looking statements. Forward-looking statements involve risks and uncertainties, including, without limitation, risks inherent in the development and/or commercialization of potential products and the management of collaborations, regulatory approvals, need and ability to obtain future capital, application of capital resources among competing uses, and maintenance of intellectual property rights. Actual results may differ materially from the results anticipated in these forward-looking statements and as such should be evaluated together with the many uncertainties that affect the company's business, particularly those mentioned in the cautionary statements found in the company's Securities and Exchange Commission filings. The company disclaims any intent or obligation to update forward-looking statements.


Key Words: Stem cells, parthenogenesis, biotechnology, skin care


http://cts.businesswire.com/ct/CT?id=bwnews&sty=20110302005480r1&sid=14230&distro=ftp

International Stem Cell Corporation
Kenneth C. Aldrich, Chairman
1-760-940-6383
kaldrich@intlstemcell.com

or
Lifeline Skin Care, Inc.
Ruslan Semechkin, PhD, President & CEO
Vice President, ISCO
ras@intlstemcell.com

Read the Rest...

ACT Awarded Patent for Stem Cell Generation Technique

§ March 6th, 2011 § Filed under Nano Medicine Comments Off on ACT Awarded Patent for Stem Cell Generation Technique

Original Article Source - Mass High Tech

Advanced Cell Technology Inc. has been given a patent for its nondestructive technique of obtaining human embryonic stem cell (hESC) lines. Called “single-blastomere” technology, the technique was referred to in a statement by ACT interim chairman and CEO Gary Rabin as “one of the most significant” among the Marlborough biotech’s more than 150 patents and patent applications.


“It will help us accelerate our progress on a number of fronts, including deriving embryonic stem cells which meet the regulatory standards of the European Medicines Agency and the US Food and Drug Administration, using the single-blastomere technology,” Rabin said, in the statement.

ACT (OTCBB: ACTC) said in a news release that its single-blastomere technique avoids embryo destruction by using a one-cell biopsy approach.

In January, the company pulled in a $25 million financing and was cleared by the FDA for its Investigational New Drug application to use hESCs in treating Dry Age-Related Macular Degeneration.

Rabin has been serving in his interim roles at ACT since mid-December, when William M. Caldwell IV, then chairman and CEO, died unexpectedly. Caldwell had held the CEO role of ACT since 2005 and the chairman post since 2006.

Read the Rest...

« Older Entries Newer Entries »



Page 55«..1020..54555657..60..»